Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like Breakthrough blood test developed for early detection of sarcoidosis February 28, 2024 Study reveals sex-specific differences in microglial response to CSF1R inhibition January 24, 2025 Income and education linked to lower post-stroke mortality May 15, 2024